BioSpace News Archive

Generic oncology sterile injectables refer to those biologics that come with active ingredients similar to that of the ones found in branded versions.

According to the report, the global in-vitro inflammatory bowel disease diagnostic market was valued at US$ 1.5 Bn in 2019. It is projected to expand at a CAGR of ~4% from 2020 to 2030.

The increasing prevalence of cancer across the world has influenced a number of markets. An important one among those is the global cancer immunotherapy market.

Aesthetics has become more important in all aspects of everyday life in the past few years. It is the most innovative branch of medicine.

Haoma Medica announced that it will present three scientific posters on NaQuinate at the American Society for Bone and Mineral Research 2020 Annual Meeting, which this year takes place as a virtual event from the 11-15 September.

Generate Biomedicines emerges from three years of stealth operations to pioneer Generative Biology™ and reimagine drug discovery and development across multiple therapeutic modalities and numerous diseases.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 22 nd Annual Investment Conference being held virtually September 14-16 2020. ProMIS’ Executive Chairman, Eugene Williams, will provide

InspireMD, Inc. announced the addition of Dr. Christina Brennan as a strategic advisor to the company to assist with planning and execution of a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States.

- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET. The slides to be p

- Revenues for full year 2020 now expected to be $8.4-8.8 billion compared to the previous outlook of $8.0-8.6 billion - Reported diluted earnings per share (EPS) for full year 2020 now expected to be $7.42-$8.92 compared to the previous outlook of $5.66-$7.66 - Adjusted diluted EPS for full year 2020 now expected to be $7.50-$9.00 compared to the previous outlook of $6.60-$8.60 - Cash provided by operations for full year 2020 now expected to be at least $1.45 billi